Relates to Heterocyclic compounds of formula (i) wherein R1 is H, alkyl (C1 - C6) optionally substituted cyclic non Aromatic, a group of 3 to 10 members, among others R2 is H, alkyl, alkoxy (C1 - C6) (C1 - C6), among others R3 is H, halogen alkoxy, (C1 - C6), among others and, X and Z are each n o CR4, where r is H, halogen, alkyl, cycloalkyl (C1 - C6) (C3, C6)Among others, W is alquileno (c1-c4), or - - W, - W - O -, among others, where W is a link or alquileno (c1-c4) a is a divalent Aromatic Ring of 5 or 6 members b is a Heterocyclic acyl or of 3 to 10 members.Preferred compounds are: trans-4 - [4 - (2 - hydroxy - 2-methylpropoxy) cyclohexyl] - 6 - [2 - (4 - oxo 4,5-dihydro - 1,2,4 - Oxadiazoles - 3 - il) biphenyl - 4-yl] methyl} - 7 - propilpirazolo [1,5-a] pyrimidine 5 (4H) - One 6 - [3 - (2 - 5 - fluoro - oxo 4,5-dihydro - 1,2,4 - Oxadiazoles - 3 - il) biphenyl - 4-yl] methyl} - 4 - trans - [4 - (2 - hydroxy - 1.2 - dimetilpro Poxi cyclohexyl) propyl] - 7 - [1,2,4] triazolo [1,5-a] pyrimidine 5 (4H) - One among others.It also relates to a Pharmaceutical composition. These compounds are angiotensin II Receptor Antagonists and agonists of the receptor? Peroxisome proliferator activated being useful in the treatment of hypertension, atherosclerosis, ObesitySE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE R1 ES H, ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO, UN GRUPO CICLICO NO AROMATICO DE 3 A 10 MIEMBROS, ENTRE OTROS R2 ES H, ALQUILO(C1-C6), ALCOXI(C1-C6), ENTRE OTROS R3 ES H, HALOGENO, ALCOXI(C1-C6), ENTRE OTROS Y, X Y Z SON CADA UNO N O CR4, EN DONDE R4 ES H, HALOGENO, ALQUILO(C1-C6), CICLOALQUILO(C3-C6), ENTRE OTROS W ES ALQUILENO(C1-C4), -O-W-, -W-O-, ENTRE OTROS, EN DONDE W ES UN ENLACE O ALQUILENO(C1-C4) A ES UN ANILLO AROMATICO DIVALENTE DE 5 O 6 MIEMBROS B ES UN ACILO O UN HETEROCICLICO DE 3 A 10 MIEMBROS. SON COMPUESTOS PREFERIDOS: 4-[TRANS-4-(2-HIDROXI-2-METILPROPOXI)CICLOHEXIL]-6-{[2-(5-OXO-4,5-DIHIDRO-1,2,4-OXADIAZOL-3-IL)BIFENIL-4-IL]METIL}-
